ArticleDrug design, development and therapy2025
Huyang Yangkun Formula Enhances Ovarian Function and Delays Reproductive Aging by Influencing Hypothalamic GnRH/LH Pulse Release Through GAT-1/GABA/GABAAR2.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Huyang Yangkun Formula (HYF), based on Yin and Yang principles, is effective in treating Premature Ovarian Insufficiency (POI) and enhancing reproduction, but its mechanism needs to be clarified. Aim: This study investigates HYF's impact on enhancing ovarian follicles development via GABA/GnRH neuron regulation. Materials and Methods: The chemical components of water extract of HYF were analyzed by combining the ultra-high performance liquid chromatography coupled with Q-Exactive mass spectrum analysis (UHPLC-QE-MS). Female SD rats received HYF for 90 days to assess changes in the ovarian function. In addition, female SD rats underwent ovariectomy to evaluated the impact of HYF or GABA treatments on LH release induced by E2 to address age-related neuroendocrine damage. Reproductive neuroendocrine markers were analyzed through immunohistochemistry and immunofluorescence. Results: HYF treatment improved the disrupted estrous cycle in aged female rats, breaking the continuous keratinized epithelial cell state and alternating between estrous periods. Aging reduces ovarian volume and follicle numbers, but after 3 months of HYF treatment, ovarian follicle development increased, and mature follicle and luteum numbers changed significantly. HYF improved sex hormone levels, advancing and enhancing the LH peak in older rats, thus boosting total 24-hour LH release. GABA injection into the lateral ventricle increased GnRH release in aging rats, highlighting GABA's excitatory role. HYF also increased GnRH secretion by reducing GAT-1, leading to more GABA release, which activates GABAAR2 receptors in GnRH neurons, enhancing their function in the hypothalamic arcuate nucleus of elderly rats. Conclusion: HYF shows promise as a treatment for improving ovarian and reproductive neuroendocrine function in early reproductive aging, providing insights into its effects on hypothalamic GnRH/LH pulse release via the GAT-1/GABA/GABAAR2/GnRH pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.